5 completed, 2 terminated. 7 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Terminated 2 |
| Phase 2 | 3 | Completed 3 |
Follow KRAS Gene Mutation: new trials by email Literature Review of KRAS Gene Mutation trials Research Report on KRAS Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer Futibatinib and Binimetinib - Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer | Phase 1 | Terminated | Taiho Oncology, Inc. | 38 | 2021-09-20 | 2024-09-19 |
| A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors Telaglenestat (CB-839), Palbociclib Oral Capsule or Tablet [Ibrance] - Solid Tumors, NSCLC | Phase 1 / Phase 2 | Completed | Calithera Biosciences, Inc | 53 | 2019-06-25 | 2022-09-19 |
| Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation Onvansertib, Bevacizumab, FOLFIRI - Metastatic Colorectal Cancer, KRAS Gene Mutation | Phase 1 / Phase 2 | Completed | Cardiff Oncology | 68 | 2019-06-24 | 2025-03-04 |
| Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer Trametinib 0.5 mg, Trametinib 1 MG, Trametinib 1.5 MG - Non Small Cell Lung Cancer, KRAS Gene Mutation | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 12 | 2018-10-09 | 2025-05-16 |
| Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations Pembrolizumab, Trametinib - KRAS Gene Mutation, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 1 | Completed | Jonathan Riess | 15 | 2018-06-26 | 2025-05-21 |
| Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation Everolimus, Neratinib, Palbociclib - Advanced Malignant Solid Neoplasm, EGFR Gene Amplification | Phase 1 | Terminated | M.D. Anderson Cancer Center | 84 | 2017-10-31 | 2026-07-22 |
| Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC. Binimetinib, Pemetrexed, Cisplatin - Advanced Non-small Cell Lung Cancer, KRAS Gene Mutation | Phase 1 | Completed | Swiss Cancer Institute | 18 | 2017-04-12 | 2021-07-14 |
Carcinoma, Non-Small-Cell Lung (3) · Colorectal Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1)
Neoplasms (6) · Neoplasms by Site (5) · Lung Diseases (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Lung Neoplasms (3) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Intestinal Diseases (1)
trametinib (3) · binimetinib (2) · palbociclib (2) · Bevacizumab (1) · CB-839 (1) · Cisplatin (1) · Everolimus (1) · IFL protocol (1) · Pemetrexed (1) · Tablets (1) · futibatinib (1) · neratinib (1) · onvansertib (1) · pembrolizumab (1) · ponatinib (1)
Calithera Biosciences, Inc (1) · Cardiff Oncology (1) · Jonathan Riess (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Swiss Cancer Institute (1) · Taiho Oncology, Inc. (1)
United States (6) · Switzerland (1)
Emil Kuriakose, MD (1) · Jonathan Riess (1) · Kathryn Arbour, MD (1) · Sarina A Piha-Paul (1)
PMID 34646387, PMID 37314501, PMID 38231047, PMID 39475591, PMID 42149426
P30CA093373 (1)